Response after just two cycles of a bortezomib-based induction therapy appears to predict depth of response at the end of induction and subsequent survival in patients with multiple myeloma. The findings, from a review of patients treated between 2009 and 2016 at Monash Health, suggest non-responders can be identified early and may require an escalation ...
Pay attention to early response in multiple myeloma
By Mardi Chapman
13 Sep 2017